What You Should Know
- The Deal: NuvemRx has acquired the 340B referral capture business of par8o (formerly owned by R1 RCM), effectively consolidating two major players in the safety-net pharmacy space.
- The Scale: The combined entity now supports over 800 covered entities nationwide, representing a cumulative patient base of 70 million lives.
- The Tech: The acquisition integrates par8o’s referral technology with NuvemRx’s platform, reportedly using AI to automate up to 85% of the complex referral and eligibility process that traditionally causes hospitals to lose 340B savings.
The “85% Automation” Promise
The core value of this acquisition isn’t just scale; it’s the reduction of administrative friction. Managing 340B compliance is notoriously labor-intensive. Tracking a patient who leaves a primary care clinic to see a specialist, ensuring that the specialist’s prescription remains eligible for 340B pricing, and documenting the “audit trail” usually requires an army of staff.
By integrating par8o’s technology, NuvemRx claims it can use AI-powered decision support to automate up to 85% of this referral and eligibility workflow.
- The Goal: To turn “leakage” into revenue. By identifying eligible prescriptions that are currently slipping through the cracks, safety-net providers can capture additional savings without increasing their headcount.
A Unified Stack for the Safety Net
This acquisition represents a maturation of the 340B market. Historically, providers had to cobble together different vendors: a Third-Party Administrator (TPA) for compliance, a separate vendor for pharmacy management, and another for referral tracking.
NuvemRx is attempting to build a “vertical stack.”
- The Combined Footprint: With par8o onboard, the company now supports more than 800 covered entities serving 70 million patients.
- The Leadership: Melissa Opraseuth, formerly COO of par8o, will join the NuvemRx leadership team, signaling that this is an integration of expertise, not just assets.
“Referral leakage and fragmented specialty care often prevent safety-net organizations from capturing the full value of the 340B program,” said Scott Seidelmann, CEO of NuvemRx. “By bringing par8o’s referral technology, enhanced with AI-powered decision support, into our suite of services, we can automate up to 85 percent of the referral and eligibility process. This offers providers another opportunity to reduce the administrative burden associated with the 340B program and allows patients to receive high-quality integrated care.”
